Is the targeted drug bochitinib effective in late-stage non-small cell lung cancer?

Pozitinib targeted drug is effective in late-stage non-small cell lung cancer. In clinical trials, bocitinib has shown the potential to extend progression-free survival and improve quality of life in the treatment of advanced non-small cell lung cancer, but the specific effect is affected by factors such as disease severity and the patient's personal constitution.

Pozitinib is effective in advanced non-small cell lung cancer

A phase II study included 50 patients with advanced non-small cell lung cancer who had point mutations or insertions in EGFR exon 20 who received pozitinib. The study met its primary endpoint, with investigator-confirmed and blinded independent review-confirmed objective response rates (ORRs) of 32% and 31%, respectively, and a median progression-free survival of 5.5 months.

Using preclinical studies, computer simulations and molecular dynamics simulations, it was found that the sensitivity of bozitinib is highly dependent on the insertion position, with proximal loop insertion being more sensitive than distal loop insertion. Clinically proven ORRs of proximal loop and distal loop are 46% and 0% respectively. Putative mechanisms of acquired resistance include EGFR T790M, MET amplification, and epithelial-mesenchymal transition (EMT).

Data indicate that is active in EGFR exon 20-mutated non-small cell lung cancer, although this activity is affected by the location of the insertion.

Effects of Pocitinib in the treatment of non-small cell lung cancer

Introduction: ERBB2 or HER2 alterations are found in approximately 2% to 5% of non-small cell lung cancer; most are exon 20 insertion mutations. The efficacy and safety of bochitinib, an oral tyrosine kinase inhibitor, was evaluated in treatment-naive patients with non-small cell lung cancer whose tumors contained HER2 exon 20 insertions.

Methods: ZENITH20 is an open-label, multi-short, multi-center, global Phase 2 trial. ZENITH20-C4 enrolled patients with untreated non-small cell lung cancer harboring a HER2 exon 20 insertion. Take 16 mg once daily (QD) or 8 mg twice daily (BID). The primary endpoint was independent center-reviewed objective response rate (ORR). Secondary and exploratory endpoints include disease control rate, duration of response, progression-free survival and safety.

Results: There were 80 patients, the disease control rate was 73%, and 80% of the patients had tumor shrinkage. The median duration of response was 5.7 months, and the median progression-free survival was 5.6 months. The most common grade 3 treatment-related adverse events were rash, stomatitis, and diarrhea.

Conclusion: Bochitinib was found to have clinically meaningful efficacy in untreated non-small cell lung cancer patients carrying HER2 exon 20 mutations, with controllable toxicity.

Posicitinib usage and dosage

1. How to take the drug: Pozitinib is provided in the form of 8mg tablets and 2mg tablets, so the medication is taken orally. The patient should swallow the tablet whole, and the tablets should not be crushed, crushed or chewed.

2. Administration time: Bochitinib is administered once a day and should be taken at about the same time every day to help maintain the blood concentration of the drug in the body and fully exert its efficacy.

3. Dosage: The recommended dose of bochitinib is 16mg. If the patient cannot tolerate the toxicity or adverse reactions of the drug, the dose can be reduced under the guidance of a doctor.

4. Missed dose: If the patient misses a dose, the dose can be taken at any time, but at least 8 hours before the next scheduled dose.

The above usage and dosage are from the US FDA drug instructions and are for reference only. Patients should follow the doctor's instructions for specific usage and dosage.

Summary

Pocitinib has a certain effect on advanced non-small cell lung cancer, but because each patient’s situation is different, the specific treatment effect varies from person to person. It is recommended that patients undergo treatment under the guidance of a doctor to avoid improper use of medication that may harm their health.

Recommended hot articles: